ACTON, Mass., November 15, 2024--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products ...
Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...
Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...
GlobalData on MSN2mon
Insulet Omnipod cleared by FDA for type 2 diabetesthe global market for insulin pumps is estimated to stand at $7bn, with that figure set to rise to $11.1bn by the end of 2030 ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today ...
With little direct competition in patch pumps, Insulet has been able to convert more users, especially patients on multiple daily injections, to its innovative, tubeless insulin pump. The firm is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback